Patrick Soon-Shiong merges troubled 'moon shot' NantKwest and cell therapy play ImmunityBio in late-stage expansion

Once one of the hottest brands in biotech, Patrick Soon-Shiong’s next-gen cancer brainchild NantKwest has taken its lumps in recent years with little to show from its natural killer cell platform. Now, with his cell therapy play ImmunityBio moving much faster in the clinic, Soon-Shiong will merge the two companies together to streamline their market aspirations.